Fatty Liver Index vs. Biochemical-Anthropometric Indices: Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease with Non-Invasive Tools

被引:0
|
作者
Demirci, Selim [1 ]
Sezer, Semih [1 ]
机构
[1] Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Dept Gastroenterol, TR-06200 Ankara, Turkiye
关键词
anthropometry; metabolic dysfunction-associated steatotic liver disease (MASLD); non-invasive diagnosis; triglyceride-glucose index; fatty liver index;
D O I
10.3390/diagnostics15050565
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a significant global burden, attributed to its increasing prevalence and strong correlation with metabolic syndrome and related conditions. Timely diagnosis and intervention are essential for minimizing the impact of MASLD. This study sought to analyze the efficacy of advanced anthropometric indices and non-invasive steatosis markers in diagnosing MASLD. Methods: This cross-sectional retrospective study evaluated the data from 578 Turkish patients admitted to our gastroenterology clinic. MASLD was diagnosed based on internationally recognized criteria. The evaluated parameters included body mass index (BMI); waist-hip ratio (WHR); waist-height ratio (WHtR); body roundness index (BRI); conicity index (CI); a body shape index (ABSI); visceral adiposity index (VAI); abdominal volume index (AVI); lipid accumulation product (LAP); fatty liver index (FLI); hepatic steatosis index (HSI); and triglyceride-glucose index (TyG) and its variants TyG-waist circumference(WC) and TyG-BMI. Results: Among 215 men, 103 (56.9%) met the criteria for MASLD, while 260 out of 363 women (65.5%) fulfilled the criteria. In the receiver operating characteristic (ROC) analysis for identifying MASLD, TyG-WC (0.826), TyG-BMI (0.820), and FLI (0.830) achieved the highest area under the curve (AUC) values, with statistically significant differences observed in their pairwise comparisons against the other parameters. Conclusions: TyG-WC and TyG-BMI are comparable to FLI in terms of simplicity of calculation and superior diagnostic accuracy, making them valuable non-invasive alternatives for MASLD screening and diagnosis.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Healthy Lifestyle and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of the Efficacy of Fatty Liver Regression
    Wang, Jingwei
    Zhao, Jinli
    Zhong, Yueyuan
    He, Chengyue
    Hu, Fen
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2025, 16 (02)
  • [42] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255
  • [43] From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
    Razzak, Iyiad Alabdul
    Noureddin, Mazen
    Trivedi, Hirsh D.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [44] Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
    Loomba, Rohit
    Wong, Vincent Wai-Sun
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 150 - 156
  • [45] Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis
    Chen, Jiaxin
    Jian, Linge
    Guo, Yangkun
    Tang, Chengwei
    Huang, Zhiyin
    Gao, Jinhang
    ANTIOXIDANTS, 2024, 13 (06)
  • [46] Mechanobiology in Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity
    Rudolph, Emily L.
    Chin, LiKang
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (07) : 7134 - 7146
  • [47] Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Nendouvhada, Livhuwani P.
    Sibuyi, Nicole R. S.
    Fadaka, Adewale O.
    Meyer, Samantha
    Madiehe, Abram M.
    Meyer, Mervin
    Gabuza, Kwazikwakhe B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [48] Metabolic dysfunction-associated steatotic liver disease and gut microbiota
    Petryna, Vitalii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S285 - S285
  • [49] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03) : 452 - 464
  • [50] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)